drugset
drugset / Trial / NCT05552755

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

NCT05552755 ↗

Phase 1/2 Recruiting 67 enrolled Recursion Pharmaceuticals Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, two-part trial in participants with FAP.

Timeline

Start
2023-07-10
Primary completion
2027-06
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-733 Small molecule 4 mg Oral
Subject TAK-733 Small molecule 8 mg Oral

Indications

classic familial adenomatous polyposis